Answers are grounded in this paper and cite their sources.
Background Therapeutic resistance to immune checkpoint blockade in melanoma is frequently associated with defective dendritic cell licensing and impaired generation of durable tumor-reactive CD8 + T cell immunity. Local mRNA-LNP delivery provides a strategy to impose transient immunomodulatory programs within tumors while limiting systemic cytokine exposure. We investigated whether intratumoral co-administration of separately formulated IL-12 and Flt3L mRNA-LNPs could induce effective immunity in anti-PD-1-refractory melanoma. Methods Cytokine expression and immune activation were assessed in tumor cells, dendritic cells and macrophages. Therapeutic activity was evaluated in 5555 Braf V600E melanoma and B16F10 models, with or without anti-PD-1. Flow cytometry, RT-qPCR, ELISA, combined CD4/CD8 depletion, NK cell depletion, cDC1-deficient Irf8 +32kb−/− mice and BMDC/OT-I co-cultures were used to define immune responses and cellular requirements. Results Both formulations supported cytokine protein production. Co-administered IL-12/Flt3L mRNA-LNPs induced complete regressions and prolonged survival in 5555 melanoma, with or without anti-PD-1, and conferred protection against rechallenge. Benefit depended on treatment intensity. Treatment also prolonged survival in B16F10 melanoma, supporting activity in an additional model. On-treatment profiling identified local IL-12 p70 production, increased cDC1 prevalence, NK cell maturation and CD8 + T-cell activation. Loss of T cells, NK cells or cDC1s abolished therapeutic efficacy. In vitro, mRNA-LNP-conditioned BMDCs enhanced antigen-dependent OT-I activation and proliferation and altered TCF1–TIM3-defined T cell states. Conclusions Intratumoral co-administration of IL-12 and Flt3L mRNA-LNPs engages an endogenous cDC1- and lymphocyte-dependent response capable of controlling anti-PD-1-refractory melanoma. These findings support complementary, mRNA-based, local cytokine delivery as a strategy to coordinate innate and adaptive antitumor immunity.
No takes yet. Share an insight, caveat, or question.
Gazzillo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: